<DOC>
	<DOCNO>NCT01664273</DOCNO>
	<brief_summary>Gene transfer electroporation ( gene electrotransfer ) use short electric pulse transiently permeabilise cell membrane enable passage plasmid DNA cell cytosol . It efficient non-viral method gene delivery various tissue . In phase I dose-escalating study , patient treat intramuscular gene electrotransfer plasmid AMEP . Plasmid AMEP encode protein AMEP bind α5β1 og αvβ3 integrins . Primary end point trial safety secondary end point efficacy , pharmacokinetics evaluation potential discomfort associate treatment procedure use VAS ( Visual Analogue Scale ) .</brief_summary>
	<brief_title>Gene Electrotransfer Muscle With Plasmid AMEP Patients With Disseminated Cancer</brief_title>
	<detailed_description>Cohorts 3 patient treat increase dos plasmid AMEP . Up 12 patient treat . Treatment procedure : Local anesthetic apply m. quadriceps femoris ( thigh muscle ) skin . An incision skin perform followed dissection muscle expose . The surgical procedure perform plastic surgeon . Plasmid AMEP inject intramuscularly immediately follow application electric pulse via needle electrode insert muscle . A combination one high voltage pulse ( 700V/cm , 100 µs ) follow one low voltage pulse ( 80 V/cm , 400 m ) apply . The wound suture dress apply . Treatment procedure estimate 30 minute . All patient hospitalize 24 hour treatment purpose evaluation vital sign , physical examination , AE SAE record pharmacokinetics sample ( blood urine ) . Blood biochemistry include LDH CK take 24 hour post treatment . ECG take treatment . Patients score discomfort pain treat area use VAS .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Age &gt; 18 year . Performance status &lt; 1 ( ECOG ) . Histologically confirm malignant tumor ( solid tumor ) histology , Metastatic disease . Patients asymptomatic brain metastasis eligible . Patient offer standard treatment . Patient eligible standard treatment available patient wish receive standard treatment . Life expectancy ≥ 3 month . Measurable disease define least one measurable lesion accord RECIST 1.1 Patient adequate organ function : Adequate bone marrow function : Neutrophil count ≥ 1.0 x 109/l ( ≤ grade 2 CTCAE 4.0 ) ; Platelet count ≥ 75 x 109/l ( &lt; grade 2 CTCAE 4.0 ) ; Hemoglobin ≥ 6,0 mmol/l . Liver : ALAT ASAT &lt; 3 ULN ( &lt; grade 2 CTCAE 4.0 ) ; Bilirubin ≤ 1,5 ULN ( &lt; grade 2 CTCAE 4.0 ) ; APTT within normal range ; INR ≤ 1,2 ( &lt; grade 1 CTCAE 4.0 ) Kidney : Plasma creatinin ≤ 1.5 ULN ( &lt; grade 2 CTCAE 4.0 ) At least 4 week since anticancer treatment . Men woman reproductive age must use effective contraception study least 6 month administration plasmid AMEP . Patient able understand participant information able comply protocol requirement schedule visit . Signed informed consent . Allergy anaesthetic use . Clinical sign active infection . Implanted pacemaker , defibrillator implant electronic device . Participation clinical trial involve experimental drug participation clinical trial within 4 week initiation study treatment . AMI ( acute myocardial infarction ) , stroke acute ischemic event within last 6 month . Severe atherosclerosis , significant cardiovascular disease ( NYHA III IV ) significant arrhythmia . Systolic blood pressure 180 mm Hg and/or diastolic blood pressure 110 mm Hg . If BP &gt; 180/110 mm Hg medical correction allow patient include BP &lt; 180/110 mm Hg . Pregnancy lactation . Clinically significant coagulopathy . Treatment anticoagulant drug . Other disorder investigator find incompatible participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>electroporation</keyword>
	<keyword>gen electrotransfer</keyword>
	<keyword>muscle</keyword>
	<keyword>plasmid AMEP</keyword>
</DOC>